ArticleNature communications2024
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.Materials today. Bio · 2026Review
- Overcoming barriers to bladder preservation: Emerging intravesical therapies for high-risk non-muscle-invasive bladder cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Article
- Synergistic magneto-enzymatic propulsion enables multimodal nanomotor swarms.Nature communications · 2026Article
- Enzymatic Nanomotors Integrated with Plant Extracts: Biochemical Mechanisms, Applications, and Clinical Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation.EMBO molecular medicine · 2026Article
- Self-propelled nanozyme motors for targeted therapy of radiation cystitis by disrupting the inflammation-cfDNA vicious cycle.Journal of nanobiotechnology · 2026Article
- Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth.Nano letters · 2026Article
- Nature-Inspired Solutions: Biomimetic Materials and Adaptive Devices for Precision Urinary Oncology.Cancers · 2026Review
- Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.Science advances · 2026Article
- Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges.Journal of nanobiotechnology · 2026Review
- Cascade-driven nanomotor with self-amplifying necrosis targeting and deep tumor penetration for enhanced type I photodynamic immunotherapy.Materials today. Bio · 2026Article
- Embodied Cross-Domain Intelligence in Biomedical Microrobots: A Review.Cyborg and bionic systems (Washington, D.C.) · 2026Review
- Targeting innate immunity to overcome immune evasion in HPV-associated cancers.Frontiers in cellular and infection microbiology · 2026Review
- Bioengineering strategies to enhance BCG immunotherapy against bladder cancer.Frontiers in immunology · 2026Review
- Active Propelled Micro Robots in Drug Delivery for Urologic Diseases.Micromachines · 2025Review
- Navigating Cancer Treatment: A Journey from 2D to 3D Cancer Models and Nanoscale Therapies.ACS pharmacology & translational science · 2025Review
- Advances in nanomaterials for enhancing cGAS-STING pathway mediated anti-tumor treatment.Materials today. Bio · 2025Review
- Nanomedicines for the treatment of genitourinary neoplasms.Materials today. Bio · 2025Review
- Micro/Nano-Motors for Enhanced Tumor Diagnosis and Therapy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most non-muscle invasive bladder cancers have been treated by transurethral resection and following intravesical injection of immunotherapeutic agents. However, the delivery efficiency of therapeutic agents into bladder wall is low due to frequent urination, which leads to the failure of treatment with side effects. Here, we report a urease-powered nanomotor containing the agonist of stimulator of interferon genes (STING) for the efficient activation of immune cells in the bladder wall. After characterization, we perform in vitro motion analysis and assess in vivo swarming behaviors of nanomotors. The intravesical instillation results in the effective penetration and retention of nanomotors in the bladder. In addition, we confirm the anti-tumor effect of nanomotor containing the STING agonist (94.2% of inhibition), with recruitment of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.